Dowe need another heart failure biomarker: focus on soluble suppression of tumorigenicity 2 (sST2)

被引：24
|
作者：
Maisel, Alan S. [1 ,2 ]
Di Somma, Salvatore [3 ]
机构：
[1] San Diego Vet Affairs Med Ctr, Div Cardiol, Vamc 3350 La Jolla Village Dr, San Diego, CA 92161 USA
[2] Univ Calif San Diego, Vamc 3350 La Jolla Village Dr, San Diego, CA 92161 USA
[3] Sapienza Univ, Sch Med & Psychol, Emergency Med St Andrea Hosp, Dept Med Surg Sci & Translat Med, Rome, Italy
来源：
EUROPEAN HEART JOURNAL | 2017年 / 38卷 / 30期
关键词：
NATRIURETIC PEPTIDE LEVELS; FAMILY-MEMBER ST2; EMERGENCY DIAGNOSIS; PROGNOSTIC VALUE; TROPONIN; THERAPY; PROCALCITONIN; GALECTIN-3; MORTALITY; PROTEIN;
D O I：
10.1093/eurheartj/ehw462
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
[No abstract available]
引用
收藏
页码：2325 / 2332A
页数：9
相关论文
共 50 条
  • [1] Soluble Suppression of Tumorigenicity-2 (sst2) Predicts Mortality and Right Heart Failure in Lvad Patients
    Numan, L.
    Aarts, E.
    Ramjankhan, F.
    Van der Meer, M. G.
    Oerlemans, M.
    De Jonge, N.
    Oppelaar, A.
    Kemperman, H.
    Asselbergs, F.
    Van Laake, L. W.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2023, 42 (04): : S364 - S365
  • [2] The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation
    Liu, Jia-Hui
    Han, Qian-Feng
    Mo, De-Gang
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2022, 65 (03) : 591 - 592
  • [3] The progress of the soluble suppression of tumorigenicity 2 (sST2) in atrial fibrillation
    Jia-Hui Liu
    Qian-Feng Han
    De-Gang Mo
    Journal of Interventional Cardiac Electrophysiology, 2022, 65 : 591 - 592
  • [4] IL-33 (Interleukin 33)/sST2 (Soluble Suppression of Tumorigenicity 2) Axis in Hypertension and Heart Failure
    Ghali, Rana
    Altara, Raffaele
    Louch, William E.
    Cataliotti, Alessandro
    Mallat, Ziad
    Kaplan, Abdullah
    Zouein, Fouad A.
    Booz, George W.
    HYPERTENSION, 2018, 72 (04) : 818 - 828
  • [5] The Continuation of Trickle-Down Medicine: Soluble Suppression of Tumorigenicity-2 (sST2) in Pediatric Heart Failure
    Greenway, Steven C.
    CANADIAN JOURNAL OF CARDIOLOGY, 2019, 35 (06) : 692 - 693
  • [6] Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure-A Prospective Observational Study
    Dworok, Victoria
    Haehnel, Valentin
    Bannehr, Marwin
    Paar, Vera
    Edlinger, Christoph
    Lichtenauer, Michael
    Butter, Christian
    Haase-Fielitz, Anja
    JOURNAL OF CLINICAL MEDICINE, 2023, 12 (23)
  • [7] Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
    Hildenbrand, Florian F.
    Illi, Barbara
    von Felten, Stefanie
    Bachofner, Jacqueline
    Gawinecka, Joanna
    von Eckardstein, Arnold
    Mullhaupt, Beat
    Mertens, Joachim C.
    Blumel, Sena
    BMC GASTROENTEROLOGY, 2024, 24 (01)
  • [8] Evaluation of soluble suppression of tumorigenicity 2 (sST2) as serum marker for liver fibrosis
    Florian F. Hildenbrand
    Barbara Illi
    Stefanie von Felten
    Jacqueline Bachofner
    Joanna Gawinecka
    Arnold von Eckardstein
    Beat Müllhaupt
    Joachim C. Mertens
    Sena Blümel
    BMC Gastroenterology, 24
  • [9] A biomarker for bacteremia in pregnant women with acute pyelonephritis: soluble suppressor of tumorigenicity 2 or sST2
    Chatterton, Carolyn
    Romero, Roberto
    Jung, Eunjung
    Gallo, Dahiana M.
    Suksai, Manaphat
    Diaz-Primera, Ramiro.
    Erez, Offer
    Chaemsaithong, Piya
    Tarca, Adi L.
    Gotsch, Francesca
    Bosco, Mariachiara
    Chaiworapongsa, Tinnakorn
    JOURNAL OF MATERNAL-FETAL & NEONATAL MEDICINE, 2023, 36 (01):
  • [10] Effectiveness of Trimetazidine in Patients with Chronic Heart Failure Stratified by the Expression of Soluble Suppression of Tumorigenicity-2 (sST2): A Prospective Cohort Study
    Zhu Min
    Liu Xuelu
    Zhang Ran
    Shu Qiuhong
    Meng Yong
    Advances in Therapy, 2022, 39 : 5514 - 5529
12345